Newsroom
GEN and Sulfateq shared the positive results from the multiple-dose Phase 1 study of SUL-238 at CTAD 2025
GEN Announces New Positive Phase 1 Trial Data of the Investigational Drug SUL-238 for Alzheimer’s and Other Neurodegenerative Diseases. Ankara, Türkiye, December 02, 2025 – GEN Pharmaceuticals (GENIL.IS), Türkiye’s leading specialty pharmaceutical...
SUL-compounds: first-in-class mitochondria-targeted medicines as potential treatment for cardiac and vascular pathologies
There is another medical need application of the SUL-compound group with SUL-150, a compound closely related to SUL-238. Recently, a new scientific paper has been published in The International Journal of Molecular Sciences about the potential of...
GEN and Sulfateq BV Announce Positive Phase 1 Trial Data on Investigational Drug SUL-238 for Alzheimer’s and Other Neurodegenerative Diseases
SUL-238, a first-in-class medicine, protects from ageing
We are happy to share great news! SUL-238 is currently in Phase I clinical trials in collaboration with our Turkish partner GEN Ilac. It is the first drug reported that leads to persisting improvement of vascular aging. This work has recently been...
SUL-238 featured in Nature Medicine
We are excited to announce that our lead drug candidate SUL-238 has been featured in the prestigious journal Nature Medicine. The article highlights hibernation as a source of inspiration for drug development, which also forms the basis for our...
Waarom hebben mensen geen winterslaap?
https://open.spotify.com/episode/7sC62GDjmc0g2oQFu4XZo0